SAN CARLOS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Marc. R Theoret, M.D. to assume the newly created position of Senior Vice President, Regulatory Strategy, where he will focus on clinical regulatory strategy for Iovance’s pipeline. Effective immediately ...

[Applause] All right. So, today I'm going to talk to you about cancer and about three very important words. You have cancer.I remember those words sort of tumbling out of my mouth. They weren't elegantly polished in the way I had sort of learned in medical school, actually here at Duke, sitting in the building across the street. They didn't have any of the the poignant pauses that I had practiced in the mirror on my first day as a doctor at the University of Chicago.None of the elegance, just words. Sort of ...

Advances in detecting cancer recurrence uh earlier and uh more accurately are transforming how the disease is treated and monitored. One of the companies on the leading edge is Nera. Joining us now, Nera CEO Steve Chapman.The company is celebrating 10 years since going public on the NASDAQ and you got a a real market cap uh at this point and some really good um not only peer-reviewed research, you've got a product. Uh I think you were cash did you have a profit or at least cash flow positive at this point. ...

Unleashing the Potential of Immuno-Oncology Therapies June 5, 2025 © 2025 Xilio Therapeutics, Inc. 1 Forward-Looking Statements and Disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, timing and expectations related to: development timelines and anticipated milestones for Xilio's programs; the receipt of future contingent payments under Xilio's coll ...

[Musica] [Musica] Buonasera. Buonasera. Grazie a tutti.È un onore per me essere qui e cercherò in questi in questi minuti di presentarvi la bellezza del di quello che ho trovato nel mio mondo. Avete mai pensato che il luogo più fantastico, più visionario, più irraggiungibile in realtà sia già dentro di noi. Eh, non è una galassia lontana, non è un'intelligenza artificiale, non è nemmeno un multiverso, ma è un cervello umano.Eh, io lo vedo ogni giorno, lo studio, lo tocco, lo opero. Io, come avete sentito, s ...

Enrollment is now underway across multiple clinical sites, in partnership with Syneos HealthVANCOUVER, Washington, June 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the first patient has been dosed in the Company’s clinical trial evaluating the efficacy of leronlimab in patients with relapsed/refractory microsatellite stable c ...

REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the presentation of new preclinical data on its novel CAPTN-3 tri-specific antibody platform in a poster presentation at the 2025 Annual Congress of the European Association for Cancer Research (EACR 2025), that was held in Lisbon, Portugal fr ...

– If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors – – Decision from European Commission expected in the third quarter of 2025 – STAMFORD, Conn., June 20, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHM ...

If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy1,2Recommendation based on CABINET Phase III trial results, which demonstrated statistically significant and clinically meaningful reductions in risk of disease progression or death with Cabometyx versus placebo3,4European Commission decision expected Q3 2025 PARIS, FRANCE, ...

NASDAQ: LNTH Lantheus Investor Presentation BUILDING ON OUR FOUNDATION TO POWER THE FUTURE OF RADIOPHARMACEUTICALS 2025 Truist Securities MedTech Conference June 17, 2025 © 2025 Lantheus. All rights reserved. Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor ...